---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-234458"
form_type: "8-K"
ticker: "BNTC"
cik: "0001808898"
company_name: "Benitec Biopharma Inc."
filed_at: "2024-10-08T23:59:59+00:00"
generated_at: "2026-05-30T18:13:27.802171+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Benitec Biopharma gets ~$21.1M from Suvretta warrant exercise; shares outstanding rise to 17.9M

## Summary
- Suvretta Capital waived 19.99% beneficial ownership limit on warrants; new cap set at 49.9%.
- Exercised 588,236 Series 2 warrants at $1.9299, 5,181,347 warrants at $3.86, and 1,368,180 pre-funded warrants at $0.0001.
- Issued total 7,137,763 shares to Suvretta funds for aggregate proceeds of ~$21.1 million.
- Outstanding common stock increased to 17,893,765 as of Oct 8, 2024, from ~10.6 million prior.

## SEC filing metadata
- accession: 0001193125-24-234458
- form_type: 8-K
- ticker: BNTC
- cik: 0001808898
- company_name: Benitec Biopharma Inc.
- filed_at: 2024-10-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808898/000119312524234458/0001193125-24-234458-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808898/000119312524234458/d878957d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-234458
- JSON: https://secwatch.observer/filing/0001193125-24-234458.json
- Plain text: https://secwatch.observer/filing/0001193125-24-234458.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.